Squarepoint’s Vertex Pharmaceuticals VRTX Stock Holding History

Squarepoint’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.28M	Sell	5,100 -500	-9%	-$233K	﹤0.01%	2087
2025 Q4	$2.54M	Sell	5,600 -13,900	-71%	-$5.99M	﹤0.01%	1895
2025 Q3	$7.64M	Buy	19,500 +8,200	+73%	+$3.43M	0.01%	1217
2025 Q2	$5.03M	Buy	11,300 +4,200	+59%	+$1.94M	0.01%	1461
2025 Q1	$3.44M	Buy	7,100 +800	+13%	+$373K	﹤0.01%	1683
2024 Q4	$2.54M	Sell	6,300 -4,700	-43%	-$2.18M	﹤0.01%	2211
2024 Q3	$5.12M	Sell	11,000 -9,700	-47%	-$4.66M	0.01%	1404
2024 Q2	$9.7M	Buy	20,700 +19,600	+1,782%	+$8.51M	0.02%	964
2024 Q1	$460K	Buy	+1,100	New	+$465K	﹤0.01%	3104
2023 Q3	–	Sell	-1,400	Closed	-$493K	–	4294
2023 Q2	$493K	Buy	1,400 +300	+27%	+$101K	﹤0.01%	2628
2023 Q1	$347K	Buy	+1,100	New	+$330K	﹤0.01%	2494
2022 Q4	–	Sell	-800	Closed	-$232K	–	3639
2022 Q3	$232K	Sell	800 -5,800	-88%	-$1.67M	﹤0.01%	2623
2022 Q2	$1.86M	Buy	+6,600	New	+$1.77M	0.01%	1240

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Squarepoint's VRTX Position: Q1 2026 in Review

Squarepoint reduced its Vertex Pharmaceuticals (VRTX) stake by 98% in Q1 2026, selling an estimated $178M and leaving 6,752 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1890.

Squarepoint first reported a position in VRTX in Q2 2015 and has held it in 36 quarters since. The position peaked at $238M in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Squarepoint held 6,752 shares of Vertex Pharmaceuticals worth $3.02M as of Q1 2026.
Squarepoint sold 382,268 Vertex Pharmaceuticals shares in Q1 2026, an estimated $178M.
Vertex Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1890 holding.
Squarepoint first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 36 quarters since.
Squarepoint's Vertex Pharmaceuticals position peaked at $238M in Q3 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.